Tab. I.

Dosage, administration, and usage recommendations.

Patient Type	Schedule	Notes
Infants < 8 months at first RSV season* and < 5 kg	50 mg	For infants born just before or during the RSV season (within the first week of life), it is advisable to administer the dose before discharge from the hospital or during their initial outpatient visit
Children < 8 months at first RSV season and ≥ 5 kg	100 mg
Children between 8 and 19 months to second RSV season	1 dose**	Recommended for the second RSV season but may be given up to 24 months of age for children considered at high risk
	(50 or 100 mg)
Children who have received fewer than five doses of Palivizumab during the season	1 dose**	It is recommended to switch to Nirsevimab if not enough doses of Palivizumab have been received
	(50 or 100 mg)
Children entering the second season of RSV after receiving Palivizumab in the first season	1 dose**	It is recommended to switch to Nirsevimab in the second season; otherwise, continue with Palivizumab
	(50 or 100 mg)
Children who have received Palivizumab (less than five doses) and can receive Nirsevimab	1 dose**	Giving one dose of Nirsevimab instead of additional doses of Palivizumab is recommended
	(50 or 100 mg)
Children £ 24 months at high risk of severe RSV disease in their second RSV season or undergoing cardiac surgery/cardiopulmonary bypass	2 doses**	Two doses were administered simultaneously. In children undergoing cardiac surgery/cardiopulmonary bypass who have received a first dose within 90 days, the additional dose should be administered as soon as the child is stable after surgery [16]
	(50 or 100 mg each)
* In temperate regions of the Northern Hemisphere, the RSV season typically spans from October to early May, experiencing its peak between December and February. ** 1 dose 50 mg/0.5 ml for children < 5 kg; 1 dose 100 mg/ml for children ≥ 5 kg.